Phase 2 Leukaemia Clinical Trials
60 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 60 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2Phase 3
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Small Lymphocytic LymphomaChronic Lymphocytic Leukaemia
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 1Phase 2
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Relapsed or Resistant Acute Leukaemias
Lin BioScience, Inc90 enrolled17 locationsNCT05756322
Recruiting
Phase 1Phase 2
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Acute Myeloblastic LeukaemiaLeukemia, T-Cell
Gyala Therapeutics33 enrolled2 locationsNCT07471789
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
SarcomaCancerLeukaemia+2 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 2
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN
Institute of Hematology & Blood Diseases Hospital, China47 enrolled1 locationNCT07165769
Recruiting
Phase 2
Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Philadelphia Chromosome Negative ALLAcute Lymphobkastic LeukemiaAcute Lymphoblastic Leukaemia Recurrent
Hospital Universitario Dr. Jose E. Gonzalez12 enrolled1 locationNCT07039877
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Not Yet Recruiting
Phase 2
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol.
Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group50 enrolled1 locationACTRN12625000994482
Recruiting
Phase 1Phase 2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled36 locationsNCT05658640
Recruiting
Phase 1Phase 2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05751044
Recruiting
Phase 1Phase 2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05745714
Recruiting
Phase 1Phase 2
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukaemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20 enrolled1 locationNCT07036250
Recruiting
Phase 2
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Myelodysplastic SyndromeAcute Myeloid LeukaemiaRecipients of Allogeneic Stem Cell Transplantation+1 more
Vastra Gotaland Region100 enrolled5 locationsNCT06793410
Recruiting
Phase 2Phase 3
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Relapsed B Acute Lymphoblastic LeukaemiaRefractory B Acute Lymphoblastic Leukaemia
National University of Malaysia10 enrolled1 locationNCT03937544
Recruiting
Phase 2
CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab
Chronic Lymphocytic Leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)38 enrolled1 locationACTRN12625000387426